Home/ Assay library
EXPERIMENTAL CAPABILITIESA complete analytical view.
Built around your molecule.
Customize a program from expression and binding through aggregation, stability and fit-for-purpose sample readiness. Every measurement serves a specific research decision.
01
Expression, identity & purity
Establish whether the candidate can be produced and analytically identified at the quality needed for the planned characterization.
| Method / service | Primary output | Applicability | Scientific considerations |
|---|---|---|---|
| Sequence assessment | Sequence, predicted charge/mass, liability flags | All supported modalities | In silico prioritization; does not replace experimental characterization |
| Construct strategy & synthesis | Construct description, tags and expression design | VHH, scFv, Fab, IgG, proteins | Final scope depends on intellectual property and expression feasibility |
| Small-scale expression & purification | Yield, recovery, molecular mass and sample inventory | Modality-specific platforms | Mammalian expression may be needed for appropriate PTMs |
| SEC-HPLC / SEC-UPLC | Monomer, high-molecular-weight and fragment fractions | Soluble proteins | Detection and interpretation depend on column, buffer and concentration |
| CE-SDS / SDS-PAGE | Size, purity, subunit integrity as applicable | Antibody and protein formats | Reduced/non-reduced format selected case-by-case |
| Intact mass / peptide mapping | Identity, heterogeneity and selected liabilities | Optional / extended | Orthogonal characterization; not universally required |
02
Binding kinetics & selectivity
Go beyond a binary hit by quantifying relevant binding behavior and prioritizing specificity risk.
| Method / service | Primary output | Applicability | Scientific considerations |
|---|---|---|---|
| BLI/SPR screening | Binding response and preliminary rank | Small binder libraries | Binary detection is not necessarily a reliable quantitative Kd |
| Full SPR/BLI kinetics | k_on, k_off, Kd, curves and fit quality | Purified protein and suitable antigen | Ligand configuration, avidity and mass transport need review |
| Competition / epitope binning | Competition relationships and candidate grouping | Selected antibody programs | Assay feasibility and target reagent requirements vary |
| Cross-species / cross-reactivity | Species target binding and selected off-target panels | In vivo planning | Requires appropriate reference proteins and context |
| Cell-surface binding / function | Target engagement or functional readout | Selected programs | Optional, needs validated cells and assay-specific controls |
03
Stability, aggregation & interactions
Understand early physical stability and solution behavior before scaling into the next study.
| Method / service | Primary output | Applicability | Scientific considerations |
|---|---|---|---|
| nanoDSF / DSF | Tm, transition traces, Tonset where robust | Compatible protein and buffer | Interpretation can be format-dependent |
| DLS | Hydrodynamic size / polydispersity | Solution-formulated proteins | Concentration and scattering artifacts require review |
| SEC stress assessment | Monomer change under defined stresses | Early stability programs | Time / temperature / agitation must be specified |
| HIC / hydrophobicity | Hydrophobicity-related interaction profile | Optional | Screening proxy, not a direct PK prediction |
| AC-SINS / self-interaction | Colloidal / self-association risk flags | Format-dependent | May need orthogonal confirmation |
| Short-term stability | Changes in potency / monomer / purity | Study-specific | Storage and handling profile agreed with sponsor |
04
Study material & handoff
Prepare material with explicit requirements for the next research study, without implying regulatory grade.
| Method / service | Primary output | Applicability | Scientific considerations |
|---|---|---|---|
| Research protein preparation | Available inventory, formulation and concentration | Project-specific | Specification must be agreed in advance |
| Endotoxin / bioburden where indicated | Sample QC versus animal-protocol criteria | In vivo preparation | Acceptance limits depend on dose, route and study |
| Storage / shipping guidance | Handling notes and tested short-term stability | Where relevant | Shipping is not itself evidence of product stability |
| Integrated candidate dossier | Raw data, methods, interpretation, risk matrix | All full programs | Does not replace nonclinical regulatory package |